Diabetic nephropathy is a common, complex disease with a clear genetic predisposition. Human gene association studies are beginning to bear fruit by identifying gene loci that increase diabetic nephropathy risk. Chua et al. report a similar study in diabetic mice that reveals a major nephropathy locus on chromosome 8. Could this be a human nephropathy gene? Time will tell, but such findings will at least improve the use of mouse models of human kidney disease.
Mouse models have become a major focus of diabetic nephropathy research during the past decade. 1,2 A major reason for this emphasis has been the ease of genetic manipulation in the mouse to either enhance or interrupt the abnormal signaling and pathologic lesions of diabetic nephropathy. Th is increasing reliance on the mouse has occurred even in the face of the nearly impenetrable resistance to nephropathy of the C57BL / 6 mouse, 1,2 the workhorse of genetic murine research. Most studies of nephropathy in mice have focused on candidate pathways and singlegene manipulation to test the eff ects of those pathways on diabetic changes, but recently several studies have used less direct and more open-ended approaches to gain insight into diabetic kidney disease. Th ese include more systemic approaches in which candidate pathways are not interrogated but in which all associations with the ultimate nephropathy phenotype are sought. One such example is illuminated in the report by Chua et al. 3 
(this issue).
Th is elegantly comprehensive study used well-established gene mapping methods with an overlay of genomewide expression analysis. These tools have been critical for analysis of nonmendelian diseases in humans for which there are complex genetic susceptibilities, such as type 1 and type 2 diabetes, diabetic nephropathy itself, 4 -6 and other forms of chronic kidney disease. Such studies, including genome-wide association studies and other similarly broad genetic approaches, have identifi ed genes and gene loci associated with nephropathy in humans that lie outside the usual pantheon of pathways known to be disrupted in chronic kidney disease. Indeed, there has been an explosion of reports in the past two years that have identifi ed new nephropathy genes in humans with the use of these techniques. Perhaps the most dramatic of these are the identifi cation of uromodulin, 7 the gene encoding Tamm-Horsfall protein, and the identification of MYH9 , 8,9 a non-muscle myosin gene, as major susceptibility loci for progression of chronic kidney disease. Indeed, variants of MYH9 may explain up to 70 % of nondiabetic forms of end-stage renal disease in African Americans. 8 -10 Ironically, one of the reports identifying this locus of nondiabetic kidney disease was from the Family Investigation of Nephropathy and Diabetes (FIND) Research Group. 8 Th e FIND group has yet to fi nd such a powerful locus for diabetic nephropathy susceptibility as MYH9 is for nondiabetic disease, although a recent report identifi ed several suggestive diabetic nephropathy loci. 4 Nonetheless, it is certain that these approaches have directed our attention to genes and gene products that had hitherto been ignored as possible major participants in progression of kidney disease. Th us, these reports have already charted new fi elds of study and are likely to lead rapidly to a diagnostic reclassifi cation and perhaps novel approaches to therapy for many patients with chronic kidney disease.
As Chua and associates 3 correctly argue, the pursuit of similar studies in mice can complement these pathfi nding analyses in humans by taking advantage of the genetic and environmental uniformity of mice and the easy availability of relevant tissues from these models. Another advantage, perhaps too obvious to be noted by the authors, is that genome-wide susceptibility mapping, including genome-wide expression analysis (which has not yet been completed by the investigators), is orders of magnitude less expensive and time-consuming than similar studies in humans. Th e fi ndings of Chua et al. 3 were completed by a single research group, whereas the human genome-wide association studies have involved well-funded multicenter consortia at work for the better part of a decade. Of course, the mouse studies, even though relatively parsimonious, might be regarded as profl igate were they not to identify genes that are relevant to human progressive nephropathy.
So how did Chua et al. 3 do in that regard? Although the jury is still out, it seems relatively likely that they have hit on an important locus for nephropathy. Th eir strategy was well reasoned. Avoiding the trap of the nephropathy-resistant C57BL / 6 mouse by turning it into a perfect negative control, the investigators used the db / db type 2 diabetic nephropathy model on a relatively nephropathic genetic background, the FVB mouse (more on that later). They analyzed linkage of the clinical nephropathy phenotype to genetic loci identifi ed by singlenucleotide polymorphisms in the diabetic progeny of FVB and C57BL / 6 mice ( Figure 1 ) . In contrast to the expected identifi cation of a number of relatively small genetic contributors to nephropathy, the investigators found a single FVB locus on chromosome 8 that remarkably accounted for a major amount of the histopathologic diff erences between mice. Importantly, there was no association between this locus and non-nephropathy phenotypes such as the degree of hyperglycemia. Th e authors are currently investigating genes in the region to identify the nephropathy gene. Th en they and other investigators will be able to ascertain whether the paralog of this gene is also involved in human nephropathy.
Although promising, there are some reasons to be concerned that the chromosome 8 gene may not be directly relevant to human diabetic nephropathy. Part of this concern has to do with the peculiar issues of mouse nephropathy. As has already been noted, the C57BL / 6 mouse is particularly resistant to all types of kidney disease (at some point those protective loci need to be identified). The FVB diabetic mouse develops more signifi cant nephropathy than the C57BL / 6 mouse, but nephropathy has been variable in this strain 1 and therefore appears to be subject to environmental eff ects that could make any genetic susceptibility locus less applicable to human disease. Moreover, this strain and virtually all mouse strains develop only early glomerulopathy and do not develop substantial tubulointerstitial fi brosis or a progressive decline in glomerular fi ltration rate, so the chromosome 8 gene may be important only for such early changes. 1, 2 In addition, the diabetic FVB mice in this study developed a sudden increase in albuminuria between 21 and 24 weeks of age, the acuity of which is atypical of human diabetic nephropathy. None of this is to deny that the authors have identified an important murine nephropathy locus that will likely teach us quite a bit about the development of albuminuria and glomerulosclerosis; it just may not instruct us as much about human diabetic nephropathy, per se .
Indeed, there is a two-way street between such mouse and human studies. Traffi c in both directions can aid in elucidating the fundamental processes of diabetic nephropathy and other chronic kidney diseases. Besides determining whether nephropathy loci in mice are present in humans with disease, nephropathy genes and gene products identifi ed in human studies can be placed in susceptible murine strains, such as db / db FVB or diabetic DBA / 2 mice, 1 and the eff ects on nephropathy can be determined. In addition, interactions between mouse and human nephropathy genes can be interrogated in murine studies. Finally, putatively critical gene expression changes in human kidney diseases can be validated in mouse models. This interspecies exchange freeway should eventually help us truly understand, treat, and prevent diabetic nephropathy.
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